论文部分内容阅读
中国创新已在多个领域实现代表性突破。国内医药工业大致经历了“缺医少药”、仿制药黄金发展十年、创新药崭露头角三个阶段。在最近10年,国内医药工业已经开始逐步注重创新药的研发与投入。研发费用的快速增长是国内药企开始注重创新药研发的最明显表现。经过改革开放后近40年的发展,中国已经成为全球第二大医药市场,正从仿制药大国向创新药大国崛起。在鼓励创新的制度变革下,我们认为医药行业步入3.0时代,中国已在多个领域
China Innovation has achieved a representative breakthrough in various fields. Domestic pharmaceutical industry generally experienced “lack of medical medicine ”, generic drugs gold development ten years, innovative medicine emerge three stages. In the recent 10 years, the domestic pharmaceutical industry has begun to pay more attention to R & D and investment of innovative drugs. The rapid growth of research and development costs is the most obvious manifestation of the domestic pharmaceutical companies began to focus on research and development of innovative drugs. After nearly 40 years of reform and opening up, China has become the world’s second largest pharmaceutical market, rising from a big generic drug country to a big country of innovative drugs. Under the institutional reform that encourages innovation, we think the pharmaceutical industry entered the 3.0 era and China has been in various fields